Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) saw its stock price plunge by 9.61% in after-hours trading on November 7, 2024, despite reporting strong financial results and positive corporate updates for the third quarter and first nine months of 2024.
The biotechnology company announced total revenue of $58.6 million in the third quarter, primarily driven by $42.1 million in sales of its newly launched cancer therapy Amtagvi (lifileucel) and $16.5 million in sales of Proleukin, which is used in the Amtagvi treatment regimen. This represented a significant increase from the prior year, driven by the successful commercial launch of Amtagvi in the U.S. in February 2024.
Iovance reaffirmed its guidance for total product revenue in the range of $160 to $165 million for the full year 2024, reflecting three quarters of Amtagvi sales. The company also maintained its guidance for total product revenue in the range of $450 to $475 million for the full year 2025, the first full calendar year of Amtagvi sales.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。